RATIONALE: Interferon-γ release assays are used to diagnose tuberculosis infection. In developed countries, high rates of reversion following conversion have been described. OBJECTIVES: To assess QuantiFERON TB Gold In-Tube test (QFT) conversion and reversion dynamics in a tuberculosis-endemic setting. METHODS: Adolescents aged 12-18 years residing near Cape Town were recruited. Tuberculin skin tests (TSTs) and QFTs were performed at baseline and after 2 years of follow up. Half of the participants had TST and QFT performed at additional time points. Participants were observed for incident tuberculosis disease for up to 5 years. MEASUREMENTS AND MAIN RESULTS: Among 5,357 participants, 2,751 (51.4%) and 2,987 (55.8%) had positive QFT and TST results, respectively, at baseline. Annualized QFT and TST conversion risks were 14.0 and 13.0%, respectively, and reversion risks were 5.1 and 4.1%, respectively. Concordance was excellent for conversions (κ = 0.74), but poor for reversions (κ = 0.12). Among recent QFT converters, the magnitude of the QFT value was strongly inversely associated with risk of reversion (P < 0.0001). When longitudinal QFT data were analyzed in a cross-sectional manner, the annual risk of infection was 7.3%, whereas inclusion of reversions in the analysis showed that the actual risk of infection was 14.0%. Incident tuberculosis was 8-fold higher among QFT reverters than in participants with all negative QFT results (1.47 vs. 0.18 cases/100 person-years, P = 0.011). CONCLUSIONS: In this tuberculosis-endemic setting, annual risk of infection was extremely high, whereas QFT and TST conversion concordance was higher and QFT reversion rates were lower than reported in low-burden settings.
RATIONALE: Interferon-γ release assays are used to diagnose tuberculosis infection. In developed countries, high rates of reversion following conversion have been described. OBJECTIVES: To assess QuantiFERON TB Gold In-Tube test (QFT) conversion and reversion dynamics in a tuberculosis-endemic setting. METHODS: Adolescents aged 12-18 years residing near Cape Town were recruited. Tuberculin skin tests (TSTs) and QFTs were performed at baseline and after 2 years of follow up. Half of the participants had TST and QFT performed at additional time points. Participants were observed for incident tuberculosis disease for up to 5 years. MEASUREMENTS AND MAIN RESULTS: Among 5,357 participants, 2,751 (51.4%) and 2,987 (55.8%) had positive QFT and TST results, respectively, at baseline. Annualized QFT and TST conversion risks were 14.0 and 13.0%, respectively, and reversion risks were 5.1 and 4.1%, respectively. Concordance was excellent for conversions (κ = 0.74), but poor for reversions (κ = 0.12). Among recent QFT converters, the magnitude of the QFT value was strongly inversely associated with risk of reversion (P < 0.0001). When longitudinal QFT data were analyzed in a cross-sectional manner, the annual risk of infection was 7.3%, whereas inclusion of reversions in the analysis showed that the actual risk of infection was 14.0%. Incident tuberculosis was 8-fold higher among QFT reverters than in participants with all negative QFT results (1.47 vs. 0.18 cases/100 person-years, P = 0.011). CONCLUSIONS: In this tuberculosis-endemic setting, annual risk of infection was extremely high, whereas QFT and TST conversion concordance was higher and QFT reversion rates were lower than reported in low-burden settings.
Authors: K Shanaube; P De Haas; A Schaap; M Moyo; B Kosloff; A Devendra; E Raby; P Godfrey-Faussett; H Ayles Journal: Int J Tuberc Lung Dis Date: 2010-07 Impact factor: 2.373
Authors: H Mahomed; T Hawkridge; S Verver; L Geiter; M Hatherill; D-A Abrahams; R Ehrlich; W A Hanekom; G D Hussey Journal: Int J Tuberc Lung Dis Date: 2011-03 Impact factor: 2.373
Authors: Fiona E Kritzinger; Saskia den Boon; Suzanne Verver; Donald A Enarson; Carl J Lombard; Martien W Borgdorff; Robert P Gie; Nulda Beyers Journal: Trop Med Int Health Date: 2009-02 Impact factor: 2.622
Authors: Richard N van Zyl-Smit; Madhukar Pai; Kwaku Peprah; Richard Meldau; Jackie Kieck; June Juritz; Motasim Badri; Alimuddin Zumla; Leonardo A Sechi; Eric D Bateman; Keertan Dheda Journal: Am J Respir Crit Care Med Date: 2009-04-02 Impact factor: 21.405
Authors: John Z Metcalfe; Adithya Cattamanchi; Charles E McCulloch; Justin D Lew; Ngan P Ha; Edward A Graviss Journal: Am J Respir Crit Care Med Date: 2012-10-26 Impact factor: 21.405
Authors: R Wood; H Liang; H Wu; K Middelkoop; T Oni; M X Rangaka; R J Wilkinson; L-G Bekker; S D Lawn Journal: Int J Tuberc Lung Dis Date: 2010-04 Impact factor: 2.373
Authors: Alice Zwerling; Marcel A Behr; Aman Verma; Timothy F Brewer; Dick Menzies; Madhukar Pai Journal: PLoS Med Date: 2011-03-22 Impact factor: 11.069
Authors: Hassan Mahomed; Tony Hawkridge; Suzanne Verver; Deborah Abrahams; Lawrence Geiter; Mark Hatherill; Rodney Ehrlich; Willem A Hanekom; Gregory D Hussey Journal: PLoS One Date: 2011-03-29 Impact factor: 3.240
Authors: Sylvia M LaCourse; Lisa M Cranmer; Daniel Matemo; John Kinuthia; Barbra A Richardson; David J Horne; Grace John-Stewart Journal: J Acquir Immune Defic Syndr Date: 2017-05-01 Impact factor: 3.731
Authors: Jason R Andrews; Elisa Nemes; Michele Tameris; Bernard S Landry; Hassan Mahomed; J Bruce McClain; Helen A Fletcher; Willem A Hanekom; Robin Wood; Helen McShane; Thomas J Scriba; Mark Hatherill Journal: Lancet Respir Med Date: 2017-02-16 Impact factor: 30.700
Authors: Elisa Nemes; Virginie Rozot; Hennie Geldenhuys; Nicole Bilek; Simbarashe Mabwe; Deborah Abrahams; Lebohang Makhethe; Mzwandile Erasmus; Alana Keyser; Asma Toefy; Yolundi Cloete; Frances Ratangee; Thomas Blauenfeldt; Morten Ruhwald; Gerhard Walzl; Bronwyn Smith; Andre G Loxton; Willem A Hanekom; Jason R Andrews; Maria D Lempicki; Ruth Ellis; Ann M Ginsberg; Mark Hatherill; Thomas J Scriba Journal: Am J Respir Crit Care Med Date: 2017-09-01 Impact factor: 21.405
Authors: M E Castellanos; S Kirimunda; L Martinez; T Quach; H Woldu; R Kakaire; A Handel; S Zalwango; N Kiwanuka; C C Whalen Journal: Int J Tuberc Lung Dis Date: 2018-09-01 Impact factor: 2.373
Authors: Mark Hatherill; Thomas J Scriba; Sara Suliman; Hennie Geldenhuys; John L Johnson; Jane E Hughes; Erica Smit; Melissa Murphy; Asma Toefy; Lesedi Lerumo; Christiaan Hopley; Bernadette Pienaar; Phalkun Chheng; Elisa Nemes; Daniel F Hoft; Willem A Hanekom; W Henry Boom Journal: J Immunol Date: 2016-07-13 Impact factor: 5.422
Authors: Julian S Peters; Jason R Andrews; Mark Hatherill; Sabine Hermans; Leonardo Martinez; Erwin Schurr; Yuri van der Heijden; Robin Wood; Roxana Rustomjee; Bavesh D Kana Journal: Lancet Infect Dis Date: 2018-12-13 Impact factor: 25.071
Authors: S Jonnalagadda; S M LaCourse; P Otieno; B Lohman-Payne; E Maleche-Obimbo; L M Cranmer; G C John-Stewart Journal: Int J Tuberc Lung Dis Date: 2015-07 Impact factor: 2.373